Shanghai Model Organisms Center(SH:688265) Ge Long Hui A P P·2026-02-27 13:10Group 1 - The company, Nanmo Biology (688265.SH), reported a revenue of approximately 421.26 million yuan for the fiscal year 2025, representing a year-on-year growth of 10.50% [1] - The net profit attributable to the parent company was approximately 32.43 million yuan, showing a significant year-on-year increase of 399.29% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was approximately 9.41 million yuan, marking a turnaround from loss to profit compared to the same period last year [1] Group 2 - The domestic biopharmaceutical industry showed signs of recovery during the reporting period, contributing to an increase in the company's industrial revenue compared to the previous year [1] - The company has implemented measures such as adjusting cage layouts, controlling procurement prices, and optimizing business processes to strengthen cost control and improve operational efficiency, leading to a reduction in costs [1] - There was an increase in non-recurring gains, such as government subsidies, compared to the previous year [1]